Rapid AML Therapeutic Panel

Molecular

The Rapid AML Therapeutic Panel was designed to assess key biomarkers associated with acute myeloid leukemia (AML). It includes the following testing methodologies and markers:

Sanger Sequencing:
TP53

PCR/Fragment Analysis:
FLT3 (ITD and TKD), IDH1/IDH2, NPM1, and CEBPA

FISH Probes:
5q-, -5 (5p15, 5q31, 5q33)
7q-, -7 (Cen 7, 7q22, 7q31)
RUNX1/RUNX1T1 (ETO/AML1) t(8;21)
MLL (11q23)
PML/RARA t(15;17)
CBFB inv(16), t(16;16)
17p- (TP53 17p13.1, NF1 17q11.2)

Test reports include a summary of all results together.

Turnaround time

4-5 Days for FLT3, IDH1/IDH2, and FISH. 7-10 Days for NPM1, CEBPA, and TP53.

Level of Service

Global

New York Approved: No

Specimen Requirements

Bone Marrow Aspirate: 2-3 mL in sodium heparin tube. EDTA is acceptable.
Peripheral Blood: 5 mL in sodium heparin tube. EDTA is acceptable.
Fluids: Mix in equal parts with RPMI (specimen volume to RPMI ratio of 1:1).

Storage and Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen. For fresh samples: refrigerate before shipping and ship same day as drawn whenever possible. Do not freeze. Please select extract & hold - DNA if specimen hold service is desired.

CPT Code(s)*

Molecular: Client-bill only, if ordered concurrently with Neo Comprehensive Myeloid Disorders, or one of the NeoTYPE Heme Profiles, such as Myeloid Disorders Profile, AML Prognostic Profile, or MDS/CMML Profile. See Notes if ordered alone.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.

Last Updated: August 05, 2025

Get in touch

Our Client Services team is on hand to help. Please call us at 866.776.5907, Option 3.